About Nautilus Neurosciences ,Inc.

Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company headquartered in Bedminster, New Jersey, announced today that United States Patent and Trademark Office has issued U.S. Patent 8,097,651 entitled “Diclofenac formulations and methods of use.” This patent relates to methods and formulations for treating migraine. Additionally, methods are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.  and ,APR applied Parma Research s.a (APR), a leading drug developer and delivery technology provider based in Switzerland, announced CAMBIA (TM)(diclofenac potassium for oral solution) is now protected by an additional Orange Book listed patent through June 16, 2026. CAMBIA(TM) is approved in the United States for the acute treatment of migraine with or without aura and was launched in the United States in June 2010.

This coverage is in addition to that provided by U.S patent Nos, 7,759,394; 7,482,377; and 6,974,595.

Patent No. 8,097,651:

“Diclofenac formulations and methods of use”, Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.

Patent No. 7,759,394:

“Diclofenac formulations and methods of use”, Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.

Patent No. 7,482,377

“Pharmaceutical compositions and methods of treatment based on diclofenac”, New pharmaceutical compositions for oral use containing Diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to Diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects; in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.

CAMBIA™

CAMBIA™, a novel, water-soluble, buffered diclofenac potassium powder, is the only prescription non-steroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine. Engineered using APR’s Dynamic Buffering Technology(TM) (DBT), a patented absorption-enhancing technology, CAMBIA™ is specifically designed for fast, effective relief from the symptoms of migraine. CAMBIA™ enters the bloodstream quickly and readily achieves peak plasma concentrations, providing rapid onset of pain relief via oral therapy without increasing the patient’s total exposure to diclofenac. CAMBIA is not indicated for prophylactic therapy or for cluster headache.